Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2013 by Georgetown University
Washington Hospital Center
Information provided by (Responsible Party):
Kim W Hickey, Georgetown University Identifier:
First received: December 12, 2007
Last updated: August 5, 2013
Last verified: August 2013

This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, we will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps your pancreas secrete insulin and how well it controls blood sugar after a meal). There are only two main drug therapies (insulin injections and glyburide pills) currently used for gestational diabetes and not all women achieve good enough blood sugar control without side effects. Therefore, we hope to find out if exenatide might also be helpful in gestational diabetes.

Condition Intervention Phase
Gestational Diabetes
Drug: Exenatide
Genetic: Buccal/blood Sample Collection
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Resource links provided by NLM:

Further study details as provided by Georgetown University:

Primary Outcome Measures:
  • glycemic control through insulin, glucose, c-peptide and glucagon assays [ Time Frame: duing testing days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • TCF7L2 polymorphism [ Time Frame: During subject testing days ] [ Designated as safety issue: No ]
  • Exenatide Pharmacodynamics and Pharmacokinetics [ Time Frame: During testing days ] [ Designated as safety issue: No ]

Estimated Enrollment: 13
Study Start Date: August 2013
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Subject receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
Drug: Exenatide
10 microgram injected sub-cutaneously once
Other Name: Byetta
Genetic: Buccal/blood Sample Collection
Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
No Intervention: B
Patients given mixed meal test and blood samples drawn for laboratory testing


Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pregnant women (singleton)
  • Gestational diabetes not requiring medical therapy
  • Between 18 and 50 years of age
  • Able to give written informed consent

Exclusion Criteria:

  • Women in the first trimester of pregnancy
  • Hematocrit less than 30%
  • Current or past treatment with any hypoglycemic agent
  • Women with gastrointestinal disease or symptoms consistent with nausea, vomiting, abdominal pain or reflux requiring medical treatment.
  • Women with high triglyceride levels, history of gallbladder or pancreatic disease.
  • Clinical diagnosis or history of any renal insufficiency (or decreased creatinine clearance)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00572689

Contact: Patricia Tanjutco, MD 202-877-5811
Contact: Jason G Umans, MD, PhD 301 560 2959

United States, District of Columbia
Georgetown University Medical Center Recruiting
Washington, District of Columbia, United States, 20007
Contact: Patricia Tanjutco, MD    202-877-5811   
Principal Investigator: Jason G Umans, MD, PhD         
Washington Hospital Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: Patricia Tanjutco, MD    202-877-5811   
Principal Investigator: Jason G Umans, MD, PhD         
Sponsors and Collaborators
Georgetown University
Washington Hospital Center
Principal Investigator: Jason G Umans, MD, PhD Georgetown University Medical Center, Medstar Health Research Institute
Study Director: Maisa N Feghali, MD Washington Hospital Center
  More Information

No publications provided

Responsible Party: Kim W Hickey, Maternal Fetal Medicine specialist - Assistant professor, Georgetown University Identifier: NCT00572689     History of Changes
Other Study ID Numbers: Exenatide.GDM, 202-801-2636
Study First Received: December 12, 2007
Last Updated: August 5, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Georgetown University:
TCF7L2 polymorphism

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes, Gestational
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Pregnancy Complications
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on November 25, 2014